About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Nashville | 20,298 Studies Near You | Clareo Health

Clinical Trials LocationsNashville

Clinical Trials in Nashville

Discover 20,298 clinical trials near Nashville, Tennessee. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3161-3180 of 20,298 trials

Active Not RecruitingPhase 2< 1 mile

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.

Glabellar Lines

Eirion Therapeutics Inc.68 participantsStarted Dec 2025

Aventura, Florida, United States • West Palm Beach, Florida, United States • New Orleans, Louisiana, United States +2 more locations

TERMINATEDPhase 319 miles

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

NCT06400511

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

Famy Life Sciences, a Viatris Company477 participantsStarted Apr 2024

Pheonix, Arizona, United States • Garden Grove, California, United States • Glendale, California, United States +26 more locations

Find Trials by Condition in Nashville

Breast Cancerin Nashville Lung Cancerin Nashville Prostate Cancerin Nashville Colorectal Cancerin Nashville Melanomain Nashville Leukemiain Nashville Lymphomain Nashville Pancreatic Cancerin Nashville Ovarian Cancerin Nashville Brain Cancerin Nashville

Data from ClinicalTrials.govTerms

RECRUITINGPhase 3100 miles

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

NCT05918861

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following release from hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (up to12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Acute Coronary Syndrome

DalCor Pharmaceuticals2,000 participantsStarted Oct 2023

Alexander City, Alabama, United States • Birmingham, Alabama, United States • Fairhope, Alabama, United States +220 more locations

Active Not RecruitingPhase 2128 miles

A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

NCT06628362

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Overweight or ObeseType 2 Diabetes Mellitus (T2DM)

Carmot Therapeutics, Inc.360 participantsStarted Nov 2024

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Guntersville, Alabama, United States +67 more locations

Active Not RecruitingPhase 2/3135 miles

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

NCT06115499

This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.

Pancreatic Acinar Cell CarcinomaPancreatic AdenocarcinomaPancreatic Adenosquamous Carcinoma+4 more

Alliance for Clinical Trials in Oncology10 participantsStarted Aug 2024

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +342 more locations

RECRUITING160 miles

Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy

NCT01696721

In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that currently receives radiation and better compare the short-term and long-term benefits of different types of radiotherapy. The data collected from this study will help facilitate research on radiation therapy and allow for collaborative research. The PPCR will collect demographic and clinical data that many centers that deliver radiation therapy already collect in routine operations.

Pediatric Patients Treated With Radiation Therapy

Massachusetts General Hospital5,000 participantsStarted Jul 2012

Palo Alto, California, United States • San Diego, California, United States • San Francisco, California, United States +23 more locations

COMPLETEDPhase 3179 miles

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

NCT04458051

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168

Primary Progressive Multiple Sclerosis

Sanofi767 participantsStarted Aug 2020

La Jolla, California, United States • Los Alamitos, California, United States • Los Angeles, California, United States +274 more locations

Active Not RecruitingNA183 miles

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)

NCT05268094

COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.

Congenital Heart Disease in Children

Carelon Research300 participantsStarted Jun 2022

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +21 more locations

Active Not RecruitingPhase 3186 miles

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

NCT05949593

This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.

Geographic Atrophy

Belite Bio, Inc429 participantsStarted Jul 2023

Phoenix, Arizona, United States • Arcadia, California, United States • Beverly Hills, California, United States +46 more locations

RECRUITINGPhase 4209 miles

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946

This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.

Gestational Diabetes MellitusPregnancy, High Risk

Ohio State University1,572 participantsStarted Aug 2024

Tuscaloosa, Alabama, United States • Los Angeles, California, United States • San Francisco, California, United States +18 more locations

RECRUITINGPhase 2217 miles

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

NCT07321678

This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus

T2DM (Type 2 Diabetes Mellitus)

Ascletis Pharma (China) Co., Limited100 participantsStarted Jan 2026

Riverside, California, United States • San Jose, California, United States • Denver, Colorado, United States +5 more locations

AVAILABLE239 miles

Molgramostim Nebulizer Solution Expanded Access Program Protocol

NCT06546098

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disorder in which a material called surfactant builds up in the lungs and makes it hard to breathe. In addition to shortness of breath, people with aPAP can experience persistent cough, overwhelming fatigue, unintentional changes in weight, chest or back pain, suddenly feeling out of shape, and general discomfort. Currently, there are no approved medications for aPAP in the United States, but the symptoms of aPAP can be treated with whole lung lavage (WLL). WLL is an invasive procedure that temporarily removes surfactant, and it can result in serious consequences like trauma to the lung, a collapsed lung, and prolonged requirement for artificial ventilation. Savara is studying an investigational drug called molgramostim nebulizer solution to see if it activates the cells that help clear surfactant from the lungs, which improves oxygen transfer from the lungs to the bloodstream. Molgramostim nebulizer solution is administered by inhalation using a hand-held nebulizer. In clinical trials, molgramostim nebulizer solution has shown improvements in gas exchange and patient reported outcomes. This expanded access program will make molgramostim nebulizer solution available to adult patients with diagnosed aPAP. Access must be obtained through the treating physician. Patients will dose molgramostim nebulizer solution 300 micrograms (mcg) once daily and be followed by their physician every 3 months to assess their clinical status and report any adverse events.

Autoimmune Pulmonary Alveolar Proteinosis

Los Angeles, California, United States • Gainesville, Florida, United States • Baltimore, Maryland, United States +3 more locations

Enrolling By Invitation253 miles

Allied Cleft & Craniofacial Quality-Improvement and Research Network (ACCQUIREnet)

NCT02702869

The Allied Cleft \& Craniofacial Quality-Improvement and Research Network (ACCQUIREnet) is a group of multidisciplinary cleft teams that have implemented a system for prospective collection of outcomes data, based on the ICHOM Standard Set for the Comprehensive Appraisal of Cleft Care, CLEFT-Q, and other outcomes instruments. Participating cleft teams may analyze clinical and psychosocial outcomes related to care of the child with cleft lip and/or palate (CL/P), compare its performance with those of other cleft centers, and identify opportunities for quality improvement.

Cleft LipCleft PalateCleft Lip and Palate

Duke University1,000 participantsStarted Oct 2016

Gainesville, Florida, United States • Hollywood, Florida, United States • Orlando, Florida, United States +8 more locations

RECRUITINGPhase 3279 miles

[18F]PI-2620 Phase 3 Histopathological Study

NCT05641688

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Alzheimer Disease

Life Molecular Imaging Ltd200 participantsStarted Dec 2022

Phoenix, Arizona, United States • Sun City, Arizona, United States • Los Angeles, California, United States +22 more locations

RECRUITINGPhase 1/2325 miles

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

NCT06422923

This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.

Epilepsy, Temporal Lobe

Neurona Therapeutics10 participantsStarted Nov 2024

Little Rock, Arkansas, United States • Los Angeles, California, United States • Orange, California, United States +14 more locations

COMPLETEDPhase 1333 miles

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

NCT03605927

The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.

Graft-versus-host-diseaseGVHDGVHD, Acute

H. Lee Moffitt Cancer Center and Research Institute45 participantsStarted Feb 2019

Duarte, California, United States • Tampa, Florida, United States • Columbus, Ohio, United States

COMPLETEDPhase 1433 miles

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

NCT06130722

First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, including immune check-point inhibitors administered in single-agent or combination use.

Locally Advanced/Metastatic Solid Tumors

Suzhou Forlong Biotechnology Co., Ltd18 participantsStarted Dec 2023

Newport Beach, California, United States • San Diego, California, United States • Canton, Ohio, United States

RECRUITING500 miles

International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

NCT06174727

This multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.

Intracranial Aneurysm

Montefiore Medical Center5,000 participantsStarted Oct 2023

Coral Gables, Florida, United States • Jacksonville, Florida, United States • Sarasota, Florida, United States +8 more locations

RECRUITINGPhase 1551 miles

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

Advanced or Metastatic Solid Tumors

Innate Pharma145 participantsStarted Jan 2025

Boston, Massachusetts, United States • Hackensack, New Jersey, United States • New York, New York, United States +4 more locations

RECRUITINGPhase 1600 miles

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Systemic Lupus Erythematosus

Climb Bio, Inc.30 participantsStarted Jul 2025

Allen, Texas, United States • San Antonio, Texas, United States • Plovdiv, Bulgaria +15 more locations

PreviousPage 159 of 1015Next

Diabetes

in Nashville

Heart Diseasein Nashville